Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Clinical trial NCT07081633 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07081633
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-05
- Primary completion
- 2026-11-30
- Enrollment
- 114
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.